A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific Cibisatamab.

CPT Pharmacometrics Syst Pharmacol · 2025 · PMC12167918 · PMID 40108739

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Obinutuzumab pretreatment prior to the administration of cibisatamab showed a trend toward more patients without ADA‐driven exposure loss (48% vs. 22%) and also decreased extent of exposure loss (25% vs. 54%) compared to cibisatamab monotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.